contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


dagens-aktienyheder-0104-agillic-audientes-ascelia-pharma-og-pharma-equity-group

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

CEO, Sweden

Claus Thestrup

Head of Equities

Michael Friis

Head of Research, Stables

Rasmus Køjborg

Agillic is a Danish Software as a Service (SaaS) company within marketing technology (MarTech), headquartered in Copenhagen, Denmark. Agillic’s omnichannel marketing automation platform empowers brands to work with data-driven insights and content to create, automate and send personalised communication to millions.

Proven business cases are found in retail, finance, travel & hospitality, energy & utility, technology & software, entertainment & gaming, media & publishing, charity & NGO, and in subscription businesses across all industries.

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk:  Agillic er en dansk Software as a Service (SaaS) virksomhed inden for marketingteknologi (MarTech), med hovedkontor i København, Danmark. Agillics omnichannel marketing automation platform giver brands mulighed for at arbejde med datadrevet indsigt og indhold for at skabe, automatisere og sende personlig kommunikation til millioner af personer. Beviste forretningscases findes inden for detailhandel, finans, turisme, energi og forsyning, teknologi og software, underholdning og spil, medier og forlag, velgørenhed og NGO og i abonnementsvirksomheder på tværs af alle brancher. English:  Agillic is a Danish Software as a Service (SaaS) company within marketing technology (MarTech), headquartered in Copenhagen, Denmark. Agillic’s omnichannel marketing automation platform empowers brands to work with data-driven insights and content to create, automate and send personalised communication to millions. Proven business cases are found in retail, finance, travel & hospitality, energy & utility, technology & software, entertainment & gaming, media & publishing, charity & NGO, and in subscription businesses across all industries.

Agillic

Audientes A/S is a Danish hearing health company specializing in smart, self-fitting and affordable hearing aids and advanced hearables. Audientes’ unique hearing aid solution, Ven™ by Audientes, is available for purchase in the Indian and Nepalese markets and will be introduced in other markets in the coming years. Companion by Audientes is an advanced hearable, a consumer electronics product, that is commercially available in Europe and later in 2024 in Japan, China, and other markets. 

Audientes’ mission is to make high-quality hearing aids and hearables for hearing improvement or hearing enhancement accessible to everyone who needs them globally. Audientes is listed on Spotlight Stock Market Denmark (AUDNTS) and headquartered in Copenhagen, Denmark with a subsidiary in Hyderabad, India. For additional information please refer to the company’s websites, www.audientes.com, www.audientes.eu, or www.audientes.in.


Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk:  Audientes er en dansk teknologivirksomhed med speciale i smarte, selvtilpassende og prisvenlige høreapparater. Audientes´ unikke høreapparatløsning, Ven™ kan købes på det indiske marked, online og i detailhandlen og vil blive introduceret til det amerikanske håndkøbsmarked og andre markeder i de kommende år. Audientes’ mission er at hjælpe de omkring 500 millioner mennesker globalt, der lider af invaliderende høretab, som enten ikke har råd til at købe et af de meget dyre høreapparater på markedet, eller som i øjeblikket ikke har adgang til en løsning på deres høretab. English:  Audientes is a Danish technology company specializing in smart, self-fitting and affordable hearing aids. Audientes’ unique hearing aid solution, Ven™ by Audientes, is available for purchase in the Indian market, online and in retail, and will be introduced to the US over-the-counter market and other markets in the coming years. Audientes’ mission is to help the approximately 500 million people globally suffering from disabling hearing loss who either cannot afford to buy one of the very expensive hearing aids on the market, or who do not currently have access to a solution to their hearing loss.

Audientes

Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.

Ascelia Pharma is listed on Nasdaq Small Cap Stockholm with ticker ACE.

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk:  Ascelia Pharma er et svensk biotechselskab med fokus på lægemidler til cancer behandlinger. Selskabet udvikler og kommercialiserer lægemidler, der er målrettet mod medicinske behov som endnu ikke bliver opfyldt og har en klar udviklings- og markedsvej. Ascelia Pharma har to pipeline-produkter, nemlig Orviglance og Oncoral. Orviglance (tidligere Mangoral) er selskabets hovedprodukt. Orviglance er i et fase 3-studie og estimeres at blive godkendt i 2023. Orviglance er et nyt kontrastmiddel til MR-scanning, udviklet til at forbedre påvisning og visualisering af leverlæsioner (inklusiv lever metastaser – og primære tumorer) hos patienter med nedsat nyrefunktion. Derudover har selskabet et fase-2 studie produkt i Oncoral som estimeres at have en færdiggørelsesdato i 2024. Oncoral er en tablet som indtages dagligt med en etableret potent anti-tumor-effekt – selv i svært behandlende kræftformer med potentiale for at tilbyde bedre patientresultater. Oncoral øger patientsikkerheden i og med patienten får en mildere dosis dagligt i form af en tablet, fremfor løbende intravenøse højdosis infusioner på hospitalet. English:  Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments.  They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance (Former working name Mangoral) is their main product which is a phase 3 study with an estimated completion date in June 2022. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a phase 2 study with an estimated completion date in 2024. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.

Ascelia Pharma

Pharma Equity Group develops new medicines for the local treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The company uses repositioning of existing drugs and brings drug candidates to a clinical phase III stage, after which it is handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the company.

Pharma Equity Group

Dagens aktienyheder med Agillic, Audientes, Ascelia Pharma og Pharma Equity Group.

Dagens aktienyheder 01/04: Agillic, Audientes, Ascelia Pharma og Pharma Equity Group.
Agillic kunne i g&#xe5;r annoncere hvem der overtager posten som CFO i selskabet, efter den nuv&#xe6;rende CFO allerede i slutningen af november 2024 meldte sin afgang. Ny CFO er Jack S&#xf8;rensen, der kommer fra et andet b&#xf8;rsnoteret selskab, nemlig Evaxion Biotech, hvor han har haft rollen som Vice President for regnskab og finans.&#xa0;<a href="https://www.inderes.dk/releases/agillic-appoints-new-cfo-jack-sorensen-1">https://www.inderes.dk/releases/agillic-appoints-new-cfo-jack-sorensen-1</a>
Audientes meddelte i g&#xe5;r, at de har sikret sig kortsigtet finansiering til driften forud for at selskabet s&#xf8;ger at ny finansiering i virksomhedsobligationsmarkedet. Kapitalen er delvist hentet via frisk kapital p&#xe5; DKK 0,44 mio., samt g&#xe6;ldskonvertering p&#xe5; DKK 0,78 mio. Nye aktier og g&#xe6;ldskonverteringen er sket til kurs DKK 0,01 pr aktie. <a href="https://www.inderes.dk/releases/correction-audientes-as-secures-financing-to-support-global-operations-through-directed-issue-and-debt-conversion-of-dkk-12-million">https://www.inderes.dk/releases/correction-audientes-as-secures-financing-to-support-global-operations-through-directed-issue-and-debt-conversion-of-dkk-12-million</a>
Ascelia Pharma fasts&#xe6;tter tegningsprisen for warrant TO1, samt vilk&#xe5;r &#x2013; l&#xe6;s mere her: <a href="https://www.inderes.dk/analyst-comments/ascelia-pharma-subscription-price-for-warrant-to1-and-terms-for-exercising">https://www.inderes.dk/analyst-comments/ascelia-pharma-subscription-price-for-warrant-to1-and-terms-for-exercising</a>
L&#xe6;s vores seneste one-pager p&#xe5; Pharma Equity Group: her: <a href="https://www.inderes.dk/research/pharma-equity-group-one-pager-proof-of-concept-year-2025">https://www.inderes.dk/research/pharma-equity-group-one-pager-proof-of-concept-year-2025</a>
Disclaimer: HC Anderen Capital modtager betaling fra de n&#xe6;vnte selskaber for en digital IR/Corporate Visibility abonnementsaftale.
/Rasmus K&#xf8;jborg d. 01/04-2025 kl. 09:05.